We are live on
!
Find out more
CG
Carlyle Group Portfolio holdings
AUM
$10.6B
1-Year Est. Return
11.25%
This Fund
S&P 500
This Quarter
Est. Return
-11.85%
1 Year Est. Return
+11.25%
3 Year Est. Return
-0.47%
5 Year Est. Return
-4.92%
10 Year Est. Return
+7.54%
AUM
$4.34B
AUM Growth
-$694M
(-14%)
Cap. Flow
-$54.3M
Cap. Flow
% of AUM
-1.25%
Top 10 Holdings %
Top 10 Hldgs %
99.8%
Holding
21
New
1
Increased
1
Reduced
1
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPRB
Spruce Biosciences
SPRB
|
+$25.6M |
| 2 |
NCNA
NuCana
NCNA
|
+$849K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SLNO
Soleno Therapeutics
SLNO
|
+$72.1M |
| 2 |
EM
Smart Share Global Ltd
EM
|
+$4.34M |
| 3 |
HLVX
HilleVax
HLVX
|
+$3.59M |
| 4 |
SunPower Inc
SPWR
|
+$543K |
| 5 |
Robinhood
HOOD
|
+$234K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Industrials | 96.13% |
| 2 | Healthcare | 1.74% |
| 3 | Technology | 1.29% |
| 4 | Real Estate | 0.53% |
| 5 | Communication Services | 0.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SARO
1
StandardAero Inc
SARO
$8.89B
| $4.17B | 96.05% |
152,673,891
| – | – |
|
|
PONY
2
Pony AI Inc
PONY
$2.89B
| $53.1M | 1.22% |
2,362,447
| – | – |
|
3
Phathom Pharmaceuticals
PHAT
$873M
| $41.1M | 0.95% |
3,496,808
| – | – |
|
|
SPRB
4
Spruce Biosciences
SPRB
$120M
| $24.8M | 0.57% |
+2,896,518
| New | +$25.6M |
|
5
Invitation Homes
INVH
$17.9B
| $14M | 0.32% |
477,500
| – | – |
|
6
Getty Images
GETY
$216M
| $12.3M | 0.28% |
6,234,252
| – | – |
|
7
CubeSmart
CUBE
$9.48B
| $8.97M | 0.21% |
220,500
| – | – |
|
8
Forward Air
FWRD
$435M
| $3.14M | 0.07% |
107,214
| – | – |
|
9
Jasper Therapeutics
JSPR
$24.8M
| $2.53M | 0.06% |
1,066,189
| – | – |
|
10
Adicet Bio
ACET
$75.9M
| $2.39M | 0.06% |
184,295
| – | – |
|
|
11
SunPower Inc
SPWR
$102M
| $2.22M | 0.05% |
1,258,970
-328,497
| -21% | -$543K |
|
12
Q32 Bio
QTTB
$255M
| $2.13M | 0.05% |
1,102,741
| – | – |
|
13
Krispy Kreme
DNUT
$569M
| $1.32M | 0.03% |
340,748
| – | – |
|
14
Exicure
XCUR
$10.7M
| $1.13M | 0.03% |
281,636
| – | – |
|
|
OKUR
15
OnKure Therapeutics
OKUR
$170M
| $742K | 0.02% |
269,895
| – | – |
|
16
N-able
NABL
$899M
| $731K | 0.02% |
93,732
| – | – |
|
|
NCNA
17
NuCana
NCNA
$5.45M
| $619K | 0.01% |
133,333
+132,666
| +19,890% | +$849K |
|
|
EM
18
DELISTED
Smart Share Global Ltd
EM
| – | – |
-3,807,399
| Closed | -$4.34M |
|
|
HLVX
19
DELISTED
HilleVax
HLVX
| – | – |
-1,838,486
| Closed | -$3.59M |
|
|
20
Robinhood
HOOD
$89.7B
| – | – |
-2,497
| Closed | -$234K |
|
|
SLNO
21
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-860,980
| Closed | -$72.1M |
|
Similar funds
SGA
PF
BMSSC
EAM
WAM
HTC
CA
OIA
Carlyle Group's Q3 2025 Portfolio in Review
As of Q3 2025, Carlyle Group held 21 positions worth $4.34B, down 14% from $5.03B the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Carlyle Group's Q3 2025 filing shows 1 new, 1 increased, 1 reduced and 4 closed positions. Its largest new stake was Spruce Biosciences: 2,896,518 shares worth $24.8M. The largest sale was Soleno Therapeutics, an estimated $72.1M.
By sector, the portfolio is most concentrated in Industrials at 96% of assets, up from 96% a quarter earlier, followed by Healthcare and Technology.
- Carlyle Group's largest Q3 2025 buy was Spruce Biosciences: 2,896,518 shares worth $24.8M.
- Carlyle Group added most to NuCana in Q3 2025, an estimated $849K increase.
- Carlyle Group's biggest Q3 2025 reduction was SunPower Inc, cutting an estimated $543K.
- Carlyle Group fully exited Soleno Therapeutics in Q3 2025, selling an estimated $72.1M.
- Carlyle Group's ten largest holdings make up 100% of its $4.34B portfolio in Q3 2025.
- Carlyle Group opened 1 new position and closed 4 in Q3 2025.
- Carlyle Group's portfolio value fell 14% quarter-over-quarter to $4.34B.
Based on Carlyle Group's 13F filing for Q3 2025, filed 7 Nov 2025.